The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| IPSC | -55.73% | N/A | N/A | -97% |
| S&P | +18.33% | +108.18% | +15.79% | +65% |
Century Therapeutics, Inc. engages in the development of off-the-shelf cell therapies to advance the course of cancer care. It focuses on harnessing the power of adult stem cells to develop curative allogeneic cell therapies for cancer. The company was founded by Marcela Maus and Hiromitsu Nakauchi in 2018 and is headquartered in Philadelphia, PA.
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $0.00M | -100.0% |
| Gross Profit | -$3.20M | -19.0% |
| Gross Margin | 97.05% | 374.4% |
| Market Cap | $48.14M | -77.7% |
| Market Cap / Employee | $0.32M | 0.0% |
| Employees | 150 | -9.1% |
| Net Income | -$32.54M | -4.3% |
| EBITDA | -$31.08M | 3.1% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $56.88M | 37.2% |
| Inventory | 0 | 0.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $46.59M | -11.6% |
| Short Term Debt | $4.89M | 33.6% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | -6.64% | 24.9% |
| Return On Invested Capital | -44.47% | 19.0% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | -$27.91M | -1.1% |
| Operating Free Cash Flow | -$27.59M | -1.0% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Book | 0.74 | 0.44 | 0.25 | 0.20 | -78.45% |
| Price to Sales | 53.95 | 13.02 | 0.36 | 0.42 | -99.59% |
| Price to Tangible Book Value | 0.92 | 0.54 | 0.32 | 0.23 | -74.88% |
| Enterprise Value to EBITDA | -0.04 | 1.66 | -0.93 | 1.81 | -183.65% |
| Return on Equity | -62.6% | -73.1% | -10.5% | -10.8% | -80.74% |
| Total Debt | $54.60M | $53.83M | $52.68M | $51.48M | -8.68% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
